Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Outpatient parenteral ­antimicrobial therapy (OPAT) and the general ­physician

Gavin Barlow, DA Barr and RA Seaton
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.13-5-495
Clin Med October 2013
Gavin Barlow
1Brownlee Centre for Infectious diseases, Gartnavel General Hospital, Glasgow, UK
Roles: consultant physician and honorary senior lecturer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DA Barr
1Brownlee Centre for Infectious diseases, Gartnavel General Hospital, Glasgow, UK
Roles: specialist registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RA Seaton
1Brownlee Centre for Infectious diseases, Gartnavel General Hospital, Glasgow, UK
Roles: consultant physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: andrew.seaton@ggc.scot.nhs.uk
  • Article
  • Figures & Data
  • Info & Metrics
Loading
KEY WORDS
  • Cellulitis
  • endocarditis
  • bone and joint infection
  • antimicrobial stewardship
  • hospital at home

Key points

Outpatient parenteral antimicrobial therapy (OPAT) is an increasingly utilised, safe and effective model of care in the UK, endorsed by the Department of Health as a key antimicrobial prescribing decision within an antimicrobial stewardship programme

National and international guidelines and clinical governance standards have been published to support quality assurance in OPAT services

Several models of OPAT organisation and delivery are in use with adaptability to local circumstances

Skin and soft tissue, and bone and joint infections account for a large proportion of OPAT episodes, but a wide variety of infections including endocarditis can be treated in OPAT safely and effectively

Novel antimicrobials with long half-life are useful in OPAT and can allow convenient management of drug resistant microbes

Introduction

Outpatient parenteral antimicrobial therapy (OPAT) refers to outpatient or community-based management of an infection via the administration of an intravenous (IV) antimicrobial without an overnight hospital stay. Patients may be managed without admission or may transition to OPAT following hospitalisation. By minimising hospital stay, OPAT is increasingly recognised as a cost-efficient and acceptable management strategy for a variety of selected patients requiring either short- or medium-to long-term parenteral therapy in the UK (Table 1).1–5 This short article outlines good practice recommendations and highlights OPAT management of infections commonly encountered by physicians with acute medical duties.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Characteristics of recently published UK OPAT service cohorts.

How does OPAT normally work in the UK?

The precise structure and function of OPAT differ between services and are adaptable to local requirements. It is ­recommended that the core OPAT team includes a consultant clinician, a medically qualified infection specialist (for example an internal medicine specialist and a ­clinical microbiologist, or an infectious diseases physician holding both roles), a clinical pharmacist with antimicrobial interest and an OPAT nurse specialist with intravascular access expertise. Delivery of antimicrobials may occur in an OPAT clinic area (which will require patient transport to and from the clinic) or in the home (with the patient or carer trained to administer IV treatment or with visits from OPAT staff or community nurses). Increasingly, some aspects of OPAT (such as the management of cellulitis) are delivered in the context of an acute-­medicine-led ‘hospital at home’ service, which may encompass other lower-risk acute medical conditions, such as selected venous thrombo-embolism, chronic obstructive pulmonary disease (COPD) exacerbation and chronic cardiac failure. Selection of patients with infection who are suitable for ambulatory care is essential. Substantive considerations include infection severity, patient mobility, stability of co-morbidity and the need for ancillary management and understanding of care.

Good clinical practice recommendations for OPAT

OPAT guidelines have been produced in a number of countries and updated good clinical practice (GCP) recommendations were published for the UK in 2012, ­covering five key components of OPAT services (Table 2).6

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Summary of good clinical practice recommendations for OPAT in UK.6

Specific conditions pertinent to medical specialties and acute medicine

Skin and soft tissue infections

Cellulitis and erysipelas alone account for about 70,000 admissions to hospital in England annually.7 A large point prevalence survey of inpatient antibiotic use in Scotland found that 10% of hospitalised patients were receiving IV antibiotics, one in six of whom were being treated for skin and soft tissue infection (SSTI).8 Randomised control trial (RCT) data suggest about one-third of patients with an SSTI requiring IV anti­microbial therapy could be managed as outpatients, with equivalent clinical outcomes and higher patient satisfaction.9

Complicated and drug-resistant SSTI cases can also potentially be treated through OPAT. This has been facilitated in recent years by novel broad-spectrum antimicrobial agents with expedient pharmacokinetic properties allowing once daily dosing. In a phase III RCT establishing ertapenem for complicated SSTI treatment, 40% of patients were managed in whole or in part as outpatients.10 Similarly, in a ­retrospective analysis of data from the Cubicin® outcomes registry, 276 of 435 (63%) patients treated for SSTI with daptomycin received OPAT, with a 95.5% success rate in those with complicated SSTI.11

UK OPAT services now have extensive experience of SSTI management and are responsible for a number of service innovations. Based on population pharmaco­kinetic modelling of patients treated through OPAT, teicoplanin dosing guidelines have been developed which provide effective and convenient individualised three-times-weekly regimens, which are useful for selected SSTIs treated in OPAT.12 Specialist nurse-led outpatient management of SSTIs, including parenteral antimicrobial prescribing under a ‘patient group direction’ (PGD) protocol, may be associated with shorter duration of therapy for moderately severe cellulitis.13

Even with careful patient selection based on severity classification, failures of OPAT in SSTI are seen. In a cohort of 963 OPAT-treated SSTI cases in Glasgow, progression of infection occurred in 2.8% of patients. 6% required admission to hospital from OPAT and significant adverse events (predominantly drug reactions) were observed in 7.1%.14 This emphasises the need for accessible and well-defined pathways for prompt review and escalation of care for OPAT services managing SSTIs.

Infective endocarditis

While OPAT is being used to avoid hospital admission for SSTI, it is also of use in supporting early discharge of patients with conditions requiring more prolonged parenteral antimicrobial therapy. This use is well exemplified by the increasing practice of completing endocarditis treatment through OPAT following initial inpatient stabilisation. In contrast to SSTI, no RCT data exist for OPAT management of endocarditis. International OPAT guidelines for endocarditis recommend stringent patient selection criteria. Contraindications to outpatient therapy include the presence of a prosthetic valve, persistently positive blood cultures, congestive cardiac failure, ­vegetations greater than 10 mm in length, recurrent embolic events, conduction abnormalities and Staphylococcus aureus aetiology.15 It is, however, clear from more recent cohort reports that OPAT services are successfully treating S aureus and prosthetic valve endocarditis,16–18 and recent European Society of Cardiology recommendations do not explicitly preclude this practice (Table 3).19 It remains standard practice to initially manage endocarditis with a minimum inpatient stay of 2 weeks prior to OPAT, with the possible exception of ­clinically stable patients with ‘oral’ ­streptococcal infection. Careful follow up during OPAT and consideration of adverse drug reactions, disease progression and complications is essential.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3.

European Society of Cardiology recommendations on suitability of patients for OPAT treatment of endocarditis 2009.19

Bone and joint infection

The general physician will encounter bone and joint infections most commonly in the context of diabetic foot or vertebral ­osteomyelitis/discitis and native joint septic arthritis. Typically, such infections require a combined surgical and medical management approach, including prolonged antibiotic therapy with a significant proportion of IV therapy. The majority of such infections may be managed for a proportion of their therapy via OPAT, although the elderly, those with resistant organisms or diabetic foot disease have a greater chance of a complicated OPAT course (disease complications, drug reactions or readmission), and therefore should be carefully selected and monitored.20

Other infections

A multitude of other infections may be amenable to OPAT therapy, including bacterial meningitis (following initial inpatient management), drug resistant mycobacterial infection, complex Lyme infection21 and some imported parasitic infections.22 In particular, Gram-negative infections and extended spectrum beta-lactamase (ESBL) infections are increasingly managed via OPAT.1 These are usually in the context of a urinary tract infection (UTI)23 that is not amenable to oral therapy and reflect epidemiological change in the hospital population.

Complications of OPAT

Parenteral treatment outside an inpatient environment potentially exposes patients to a different risk profile. As with any model of healthcare delivery, complications can be anticipated and ameliorated.24 It is recommended that OPAT services systematically record adverse outcomes for quality assurance purposes.6 Many (but not all) OPAT models make use of indwelling intravascular access devices (Table 1). These are associated with line infections (at a rate of 0–3 per 1,000 OPAT patient days in published cohorts), while other line events, such as thrombosis and mechanical and chemical phlebitis, occur at higher rates (0.5–5 per 100 OPAT patient days).3,25–27 This underlines the need for specialist nursing involvement with intravascular device expertise in OPAT. Rates of healthcare associated infection (HAI) are lower than in hospitalised patients. For example, Clostridium difficile-associated disease (CDAD) is rare in OPAT patients, with rates of less than 0.5% per OPAT patient episode in UK cohorts reporting on CDAD.1–4 Overall rates of unplanned readmission from OPAT range from 6% to 12%.1–4 Appropriate and well ­supported self-administration of OPAT by patients or carers at home has not been associated with increased rates of complications.4,25

Antimicrobial stewardship and OPAT

Antimicrobial stewardship is a locally based programme to ensure safe, effective and prudent use of antimicrobials in order to optimise outcome and minimise unintended consequences such as CDAD, methicillin-resistant Staphylococcus aureus (MRSA) infection and drug-related toxicity. Following the decision to prescribe an antimicrobial, OPAT has been identified as one of the five key prescribing decisions by the Department of Health in England,28 highlighting the importance of early identification of patients who could be safely and effectively managed in a non-hospital setting. Within the OPAT programme, antimicrobial stewardship principles are similarly important, minimising unnecessarily prolonged IV therapy, promoting early switching from IV to oral treatment and, whenever possible, ­simplification of antimicrobials to the ­narrowest spectrum possible.6 It is therefore essential that every patient undergoing OPAT has an antibiotic plan and that the plan is reviewed regularly and adapted as circumstances evolve. The development of a patient group direction in skin and soft tissue infection, giving clinical nurse specialists the facility to implement a timely IV-to-oral switch without the need for medical review, has been associated with progressive reductions in the duration of IV therapy.13,14 While IV therapy is regarded as a standard of care in the management of many deep-seated infections, the relative efficacy of IV vs oral antibiotic therapy in bone and joint infections is unknown. An Oxford-initiated UK multicentre randomised study of IV vs oral treatment is currently underway and may better define the role of OPAT in this important patient group.

Acknowledgements

The Glasgow OPAT team: Lindsay Semple, Fiona Robb, Claire Vallance and Deepa Matthew.

  • © 2013 Royal College of Physicians

References

  1. ↵
    1. Barr DA,
    2. Semple L,
    3. Seaton RA
    . Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. Int J Antimicrob Agents 2012;39:407–413.doi:10.1016/j.ijantimicag.2012.01.016
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chapman AL,
    2. Dixon S,
    3. Andrews D,
    4. et al.
    Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 2009;64:1316–24.doi:10.1093/jac/dkp343
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hitchcock J,
    2. Jepson AP,
    3. Main J,
    4. Wickens HJ
    . Establishment of an outpatient and home parenteral antimicrobial therapy service at a London teaching hospital: a case series. J Antimicrob Chemother 2009;64:630–4.doi:10.1093/jac/dkp212
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Matthews PC,
    2. Conlon CP,
    3. Berendt AR,
    4. et al.
    Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother 2007;60:356–62.doi:10.1093/jac/dkm210
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Nathwani D,
    2. Morrison J,
    3. Seaton RA,
    4. et al.
    Out-patient and home-parenteral antibiotic therapy (OHPAT): evaluation of the impact of one year's experience in Tayside. Health Bull (Edinb) 1999;57:332–7.
    OpenUrlPubMed
  6. ↵
    1. Chapman AL,
    2. Seaton RA,
    3. Cooper MA,
    4. et al.
    Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 2012;67:1053–62.doi:10.1093/jac/dks003
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Health and Social Care Information Centre
    . Hospital episode statistics, admitted patient care England 2010-11: Primary Diagnosis. London: HSCIC, 2011. www.hscic.gov.uk/pubs/hesadmitted1011 [Accessed 29 August 2013].
  8. ↵
    1. Seaton RA,
    2. Nathwani D,
    3. Burton P,
    4. et al.
    Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). Int J Antimicrob Agents 2007;29:693–9.doi:10.1016/j.ijantimicag.2006.10.020
    OpenUrlCrossRefPubMed
  9. ↵
    1. Corwin P,
    2. Toop L,
    3. McGeoch G,
    4. et al.
    Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ 2005;330:129.doi:10.1136/bmj.38309.447975.EB
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Gesser RM,
    2. McCarroll KA,
    3. Woods GL
    . Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect 2004;48:32–8.doi:10.1016/j.jinf.2003.10.001
    OpenUrlCrossRefPubMed
  11. ↵
    1. Martone WJ,
    2. Lindfield KC,
    3. Katz DE
    . Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract 2008;62:1183–7.doi:10.1111/j.1742-1241.2008.01824.x
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lamont E,
    2. Seaton RA,
    3. Macpherson M,
    4. et al.
    Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother 2009;64:181–7.doi:10.1093/jac/dkp147
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Seaton RA,
    2. Bell E,
    3. Gourlay Y,
    4. Semple L
    . Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother 2005;55:764–7.doi:10.1093/jac/dki092
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Seaton RA,
    2. Sharp E,
    3. Bezlyak V,
    4. Weir CJ
    . Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents 2011;38:243–8.doi:10.1016/j.ijantimicag.2011.05.008
    OpenUrlCrossRefPubMed
  15. ↵
    1. Tice AD,
    2. Rehm SJ,
    3. Dalovisio JR,
    4. et al.
    Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004;38:1651–72.doi:10.1086/420939
    OpenUrlFREE Full Text
  16. ↵
    1. Partridge DG,
    2. O’Brien E,
    3. Chapman AL
    . Outpatient parenteral antibiotic therapy for infective endocarditis: a review of 4 years’ experience at a UK centre. Postgrad Med J 2012;88:377–81.doi:10.1136/postgradmedj-2011-130355
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Amodeo MR,
    2. Clulow T,
    3. Lainchbury J,
    4. et al.
    Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect 2009;59:387–93.doi:10.1016/j.jinf.2009.09.009
    OpenUrlCrossRefPubMed
  18. ↵
    1. Duncan CJ,
    2. Barr DA,
    3. Ho A,
    4. et al.
    Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. J Antimicrob Chemother 2013;68:1650–4.doi:10.1093/jac/dkt046
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Habib G,
    2. Hoen B,
    3. Tornos P,
    4. et al.
    Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009;30:2369–413.doi:10.1093/eurheartj/ehp285
    OpenUrlFREE Full Text
  20. ↵
    1. Mackintosh CL,
    2. White HA,
    3. Seaton RA
    . Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. J Antimicrob Chemother 2011;66:408–15.doi:10.1093/jac/dkq445
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. White B,
    2. Seaton RA,
    3. Evans TJ
    . Management of suspected Lyme borreliosis: experience from an outpatient parenteral antibiotic therapy service. QJM 2013;106:133–8.doi:10.1093/qjmed/hcs189
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Seaton RA,
    2. Morrison J,
    3. Man I,
    4. et al.
    Out-patient parenteral antimicrobial therapy – a viable option for the management of cutaneous leishmaniasis. QJM 1999;92:659–67.doi:10.1093/qjmed/92.11.659
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Bazaz R,
    2. Chapman AL,
    3. Winstanley TG
    . Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother 2010;65:1510–3.doi:10.1093/jac/dkq152
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Gilchrist M,
    2. Franklin BD,
    3. Patel JP
    . An outpatient parenteral antibiotic therapy (OPAT) map to identify risks associated with an OPAT service. J Antimicrob Chemother 2008;62:177–83.doi:10.1093/jac/dkn152
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Barr DA,
    2. Semple L,
    3. Seaton RA
    . Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2012;31:2611–9.doi:10.1007/s10096-012-1604-z
    OpenUrlCrossRefPubMed
  26. ↵
    1. Fisher DA,
    2. Kurup A,
    3. Lye D,
    4. et al.
    Outpatient parenteral antibiotic therapy in Singapore. Int J Antimicrob Agents 2006;28:545–50.doi:10.1016/j.ijantimicag.2006.08.018
    OpenUrlCrossRefPubMed
  27. ↵
    1. Hoffman-Terry ML,
    2. Fraimow HS,
    3. Fox TR,
    4. et al.
    Adverse effects of outpatient parenteral antibiotic therapy. Am J Med 1999;106:44–9.doi:10.1016/S0002-9343(98)00362-3
    OpenUrlCrossRefPubMed
  28. ↵
    Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection. Antimicrobial stewardship: ‘Start smart – then focus’. London: DH, 2011. www.gov.uk/government/uploads/system/uploads/attachment_data/file/215308/dh_131181.pdf [Accessed 5 August 2013].
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Outpatient parenteral ­antimicrobial therapy (OPAT) and the general ­physician
DA Barr, RA Seaton
Clinical Medicine Oct 2013, 13 (5) 495-499; DOI: 10.7861/clinmedicine.13-5-495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Outpatient parenteral ­antimicrobial therapy (OPAT) and the general ­physician
DA Barr, RA Seaton
Clinical Medicine Oct 2013, 13 (5) 495-499; DOI: 10.7861/clinmedicine.13-5-495
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • How does OPAT normally work in the UK?
    • Good clinical practice recommendations for OPAT
    • Specific conditions pertinent to medical specialties and acute medicine
    • Complications of OPAT
    • Antimicrobial stewardship and OPAT
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Atypical mycobacteria: an important differential for the general physician
  • Antibiotic stewardship
  • Invasive fungal infections
Show more CME SECTION Infectious diseases

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians